Clinico-epidemiological features of infections caused by CTX-M type extended spectrum beta lactamase-producing Escherichia coli in hospitalised patients

被引:8
作者
McMullan, Ronan [1 ]
Loughrey, Anne C. [1 ]
McCalmont, Mark [1 ]
Rooney, Paul J. [1 ]
机构
[1] Belfast City Hosp, Dept Med Microbiol, Belfast BT9 7AD, Antrim, North Ireland
关键词
ESBL; Escherichia coli; CTX-M; epidemiology;
D O I
10.1016/j.jinf.2006.01.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A review of medical records of 45 of 53 hospitalised patients with positive cultures for CTX-M type ESBL-producing Escherichia coli between 01 January and 31 May 2004 was conducted. The mean age of the population studied was 73.1 (+/- 14.6) years and the majority (55.6%) had been under the care of the internal medicine or elderly care service. In the majority (77.8%) of instances the isolate was attributed to a clinical infection rather than colonisation and the commonest clinical specimen to yield the organism was urine, which was positive in 57.8% of patients. Acquisition of the organism was categorised as nosocomial in 68.9% of patients; in this subgroup, the median duration of inpatient stay prior to recovery of the organism was 24 (range 3-240) days. Haemodialysis-dependence was the most common of the comorbidities evaluated. The mean number of antibiotics prescribed per patient in the 30 days prior to first isolation of the organism was 1.7 (range 0-4). Furthermore, the mean number of antibiotic-days exposure per patient during this period was 13.9 (range 0-48). The most frequently received class of antibiotic was beta-lactam/beta-lactamase inhibitor combinations. Of 35 infections, 26 (74.2%) were successfully treated. Overall 12 patients with infection died (34.3%); attributable mortality was presumed in seven (20%). (C) 2006 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 26 条
[1]   Ceftazidime-hydrolysing CTX-M-15 extended-spectrum β-lactamase (ESBL) in Poland [J].
Baraniak, A ;
Fiett, J ;
Hryniewicz, W ;
Nordmann, P ;
Gniadkowski, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (03) :393-396
[2]  
BHAVNANI SM, 2004, 44 INT C ANT AG CHEM, P372
[3]   Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes [J].
Bonnet, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :1-14
[4]   Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients [J].
Colodner, R ;
Rock, W ;
Chazan, B ;
Keller, N ;
Guy, N ;
Sakran, W ;
Raz, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (03) :163-167
[5]   Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals [J].
Edelstein, M ;
Pimkin, M ;
Palagin, I ;
Edelstein, I ;
Stratchounski, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3724-3732
[6]   Extended-spectrum β-lactamases:: Frequency, risk factors, and outcomes [J].
Einhorn, AE ;
Neuhauser, MM ;
Bearden, DT ;
Quinn, JP ;
Pendland, SL .
PHARMACOTHERAPY, 2002, 22 (01) :14-20
[7]  
Garner JS, 1996, APIC INFECT CONTROL, pA1
[8]   Bloodstream infections caused by Enterobacter species:: Predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome [J].
Kang, CI ;
Kim, SH ;
Park, WB ;
Lee, KD ;
Kim, HB ;
Oh, MD ;
Kim, EC ;
Choe, KW .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (06) :812-818
[9]  
KOTAPATI S, 2004, 44 INT C ANT AG CHEM, P373
[10]   Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for infection and impact of resistance on outcomes [J].
Lautenbach, E ;
Patel, JB ;
Bilker, WB ;
Edelstein, PH ;
Fishman, NO .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1162-1171